Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3

Previous use of a mechanistic static model to accurately quantify the increased rosuvastatin exposure due to drug–drug interaction (DDI) with coadministered atazanavir underpredicted the magnitude of area under the plasma concentration–time curve ratio (AUCR) based on inhibition of breast cancer res...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsby, Robert, Coghlan, Hannah, Edgerton, Jacob, Hodgson, David, Outteridge, Samuel, Atkinson, Hayley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944867/
https://www.ncbi.nlm.nih.gov/pubmed/36811234
http://dx.doi.org/10.1002/prp2.1060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944867/
https://www.ncbi.nlm.nih.gov/pubmed/36811234
http://dx.doi.org/10.1002/prp2.1060

Ejemplares similares